The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).
- Deploying A Vendor Life Cycle Oversight Model
- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26
- Metrics, Not Audits, Should Lead Vendor Accountability
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Sales & Operations Planning for Small Teams: Aligning Clinical Supply
- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
- Allogeneic Cell Therapy's Success Hinges On Perfecting The Platform
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Screening Peptones, Including "Titration And Blending" Protocol Examples
Dive into the importance of peptone selection, instructions for reconstituting peptone powders for mammalian cell culture, and discover starter packs containing commonly used peptones for specific applications.
-
Enabling The Rapid, Reproducible Manufacturing Of TranspoCART Cells
Learn how an innovative technology streamlines Transpocart cell production, making rapid and consistent manufacturing a reality for cell therapies.
-
Streamline Analytical Tech Transfer Through Analytical Target Profile
Analytics debt in CGT can derail timelines and budgets. Learn how early ATP planning and cross-functional alignment can eliminate costly setbacks and accelerate IND approvals.
-
A Better Immune Response To Vaccination: Using Lymphoid Follicle Organ-Chips
Discover a first-of-its-kind human LF-Chip containing B, T, plasma and antigen-presenting cells to test functional immunization responses to vaccines and adjuvants in vitro.
-
Get Full Control Of Your T Cell Isolation
This study demonstrates the automated magnetic isolation of CD4/CD8+ cells from fresh or frozen leukapheresis using a functionally closed cell processing system paired with a modular application.
-
Factors Influencing CD34+ Cell Collection Efficiency In Leukapheresis
Efficiently collecting sufficient peripheral blood stem cells is paramount for successful transplantation, necessitating a deeper understanding of influencing factors and procedural nuances.
-
Use Of Epiontis ID In A Phase 2 Psoriasis Trial
Mirikizumab’s Phase 2 trial explores IL-23 inhibition in psoriasis, measuring immune cell changes to assess its potential for long-term disease control and flare-up prevention.
-
A Digital Solution Embeds Quality Into Cellular Therapeutics Production
Discover how Dendreon cut review and release time by nearly 50% while maintaining a 99% right-first-time rate, which boosts collaboration, visibility, and operational efficiency across teams.
-
Balancing Protein A Resin Cost, Performance, And Productivity
Optimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
Innovating The mAb Characterization Process
Understanding the characteristics of a molecule's "personality" is crucial for optimizing development and manufacturing. Learn how to overcome the challenges in the characterization process.
NEWSLETTER ARCHIVE
- 01.16.26 -- Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable
- 01.15.26 -- Timing Tech Transfer With Complex Raw Materials
- 01.14.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- 01.13.26 -- STREAM Edition: A 2025 Retrospective Of The Life Science Industry
- 01.13.26 -- Allogeneic Cell Therapy's Success Hinges On Perfecting The Platform
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
- Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections